Open-Label Clinical Trial to Assess the Efficacy, Tolerability and Safety of a Single IV [intravenous] Dose of Palonosetron 0.25 mg + Dexamethasone IV in the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomit (CINV).

Trial Profile

Open-Label Clinical Trial to Assess the Efficacy, Tolerability and Safety of a Single IV [intravenous] Dose of Palonosetron 0.25 mg + Dexamethasone IV in the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomit (CINV).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2017

At a glance

  • Drugs Palonosetron (Primary) ; Dexamethasone; Dexamethasone; Methylprednisolone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 28 Jan 2009 Actual end date changed from Sep 2008 to Aug 2008 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top